الفهرس | Only 14 pages are availabe for public view |
Abstract Diabetic neuropathy (DN) is one of the debilitating microvascular complications of diabetes that is present in approximately 50% of patients. Marked increase in oxygen free radicals (OFR) results in oxidative stress that leads to development of DN. Antioxidant enzymes play a major role in protection against rapid onset and progression of DN, by reducing the excess OFR and peroxides. Mutations and variants in genes encoding such enzymes may therefore result in early onset and rapid progression of this complication. Aim: Investigating the association between Superoxide Dismutase 2 p.(Ala16Val) and superoxide dismutase 3 p. (Arg213Gly) gene variants and risk of neuropathy in Type 1 diabetic patients. Methods: Eighty type 1 diabetic patients were divided into two groups, forty patients have clinical DN (group 1), and forty patients without neuropathy (group 2). They were all tested for SOD2:p.(Ala16Val) and SOD3:p.(Arg213Gly) gene variants by Taqman Real Time PCR, and HbA1c was done to all patients |